Drugs / RSV/hMPV vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06604767 | Sep 2024 → Mar 2026 | parainfluenza infectious disease, respiratory syncytial virus infectious disease | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV/hMPV vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06604767 ↗ |
| Modality | Vaccine | “different combinations of RSV/hMPV/PIV3 or RSV/hMPV or only RSV vaccine” NCT06604767 ↗ |
| Route | Intramuscular | “Route of administration:Intramuscular” NCT06604767 ↗ |